eurocvp

2015 Congress

ROME 29-31 May 2015

Congress Venue
NH Vittorio Veneto

Cardiovascular Pharmacotherapy
ESC Working Group

EUROPEAN SOCIETY OF CARDIOLOGY®

SCIENTIFIC PROGRAMME

Scientific Rationale

There is compelling evidence that in patients with cardiovascular disease and in those with an increased cardiovascular risk comprehensive risk factor interventions extend overall survival, improve quality of life, decrease need for interventional procedures and reduce the incidence of subsequent myocardial infarction and death. Several data demonstrate that multiple risk factors have a major impact on the general population and that their multimodal modification will decrease incidence of coronary heart disease.

There is no general agreement among scientific societies on how to predict the effectiveness of specific therapies in modifying the cardiovascular risk in an individual patient. Despite the general knowledge of clinical guidelines issued by the International Societies, the vast majority of patients and of individuals at risk are not treated or not adequately treated in order to achieve treatment goals. This is probably dependent by the fact that several recommendations on primary and secondary prevention of cardiovascular disease are developed by International Societies and therefore cannot be fully applied when the political, social, economic and medical circumstances are very different. In addition, most recommendations cannot easily be followed by individual physicians as they would require a team approach in which healthcare professionals (i.e. physicians, nurses and nutritionists) manage risk reduction therapy by using follow up techniques that include clinic visits and telephone contact.

Because of the increased survival of patients with a previous cardiovascular event and cerebrovascular coupled with the progressive ageing of the general populations and the consequent increased prevalence of risk factors such as diabetes and arterial hypertension the incidence of stroke is progressively increasing. Therefore, there is the need to clarify the integrative role of specific therapeutic approaches for the prevention of cerebrovascular events in patients at increased risk of stroke.

By attending this course the audience will be able to assess the overall cardiovascular risk of each patient and to adjust treatment strategies according to patient needs The attendee will be updated on the importance of newly discovered risk factors for cardiovascular and cerebrovascular disease and of innovative approaches to their treatment.

SCIENTIFIC PROGRAMME

eurocvp 2015 Congress

ROME 29-31 May 2015

29 May 2015

14:30 – 16:45 SYMPOSIUM IN ITALIAN

Controversies in Pharmacology in Interventional Cardiology

Chairs: ***Francesco Pelliccia*** (Rome, Italy) - ***Gennaro Sardella*** (Rome, Italy)

Optimal P2Y12 Inhibitor Therapy in the STEMI patients: which drug plays the major role?

Ticagrelor
Davide Capodanno (Catania, Italy)

Prasugrel
Guido Parodi (Firenze, Italy)

Do we need pretreatment with P2Y12 Inhibitors in NSTEMI patients?

Yes we do
Leonardo De Luca (Rome, Italy)

No we don't
Leonardo Bolognese (Arezzo, Italy)

Optimal DAPT duration after DES

Treatment for 6 months is enough in all patients
Giulio Giuseppe Stefanini (Milan, Italy)

Duration depends from the patient
Giuseppe De Luca (Novara, Italy)

Anticoagulant and Antiplatelet Therapy in PCI patients with atrial fibrillation

Double therapy is here to stay
Vincenzo Pasceri (Rome, Italy)

Triple therapy still the best
Giampaolo Niccoli (Rome, Italy)

PFO Closure in 2015: where are we now?

Still a major indication
Achille Gaspardone (Rome, Italy)

Need for personalized indication
Christian Pristipino (Rome, Italy)

Discussants:
F. Andreotti (Rome, Italy) - ***G. Biondi Zoccai*** (Latina, Italy) -
A. Danesi (Rome, Italy) - ***G. Gioffrè*** (Rome, Italy) -
A. Granatelli (Rome, Italy) - ***C. Greco*** (Rome, Italy) -
M. Mancone (Rome, Italy) - ***M. Miglionico*** (Rome, Italy) -
S. Rigattieri (Rome, Italy) - ***G.M. Sangiorgi*** (Rome, Italy) -
M. Schiariti (Rome, Italy) - ***G. Speciale*** (Rome, Italy) -
F. Tomai (Rome, Italy) - ***C. Trani*** (Rome, Italy) -
N. Viceconte (Rome, Italy)

17:00-19:00 **Pre-Congress Workshop**
Basic pharmacology for cardiologists
Chairs: ***Claudio Ceconi*** (Ferrara, Italy) - ***Thomas Walther*** (Cork, Ireland)

Refresher on technical terms in cardiovascular pharmacology
Alessandro Mugelli (Florence, Italy)

The renin-angiotensin system: old guys, actual players, and newcomers
Thomas Walther (Cork, Ireland)

Drug-drug interactions: where and how
Vincenzo Mollace (Catanzaro - Italy)

19:00-19:30 **OPENING CEREMONY**
Stefan Agewall (Oslo, Norway) - ***Sven Wassmann (Munich, Germany)***

30 May 2015

9:00-10:30 **Gender differences in cardiovascular pharmacology**
Chairs: ***Juan Carlos Kaski*** (London, UK) - ***Juan Tamargo*** (Madrid, Spain)

Gender differences in pharmacokinetics / pharmacodynamics relevant to clinical effects
Vincenzo Mollace (Catanzaro - Italy)

Can we generalise to both gender the results of cardiovascular clinical trials?
Juan Tamargo (Madrid, Spain)

Different gender susceptibility to cardiovascular side effects of cardiovascular and non-cardiovascular drugs
Giuseppe M.C. Rosano (London, UK)

10:30-11:00 Coffee break

11:00-12:30 **Pharmacotherapy of lipids - update**
Chairs: ***Heinz Drexel*** (Feldkirch, Austria) - ***Basil Lewis*** (Tel Aviv, Israel)

New insights into endogenous and exogenous lipids.
New therapeutic strategies
Heinz Drexel (Feldkirch, Austria)

Lowering LDL cholesterol by combination therapy
Giuseppe M.C. Rosano (London, UK)

12:30-14:00 **Luncheon Session (box lunch served in plenary room**
What do the ESC guidelines recommend for the treatment of the difficult patient?
(clinical cases with interactive discussion)
Chairs: ***Stefan Agewall*** (Oslo, Norway) - ***Juan Carlos Kaski*** (London, UK)
Sven Wassmann (Munich, Germany)

Elderly patients with co-morbidities
Angelo Scuteri (Rome, Italy)

Patients receiving oral anticoagulants
Vincenzo Pasceri (Rome, Italy)

Renal and/or liver failure patients
Francesco Pelliccia (Rome, Italy)

14:00-14:30 **Trial highlights from the American College of Cardiology and Heart Failure Association meetings**
Basil Lewis (Tel Aviv, Israel) - ***Giuseppe M.C. Rosano*** (London, UK)

14:30-16:00 **Pharmacotherapy of Heart Failure - Joint session with the Heart Failure Association**
Chairs: ***Stefan Agewall*** (Oslo, Norway) - ***Stefan Anker*** (Berlin, Germany)

What is on the horizon for the pharmacological treatment of patients with chronic heart failure after PARADIGM-HF
Juan Tamargo (Madrid, Spain)

What treatment for heart failure with preserved ejection fraction?
Giuseppe M.C. Rosano (London, UK)

The treatment of patients with advanced heart failure
Marco Metra (Brescia, Italy)

16:00-16:30 **Coffee break and moderated poster presentations**
Chairs: ***Basil Lewis (Tel Aviv, Israel)***

16:30-17:00 **Lecture**
New developments in the treatment of acute and chronic heart failure
Stefan Anker (Berlin, Germany)

17:00-18:30 **Oral anticoagulation: from VTE to AF**
Chairs: ***Basil Lewis*** (Tel Aviv, Israel) -
Christian Torp-Pedersen (Aalborg, Denmark)

NOAC vs VKA for patients with venous thromboembolism and atrial fibrillation
Alexander Niessner (Vienna, Austria)

Anticoagulation in the difficult patient: management of PCI and concomitant antiplatelet therapy
Sven Wassmann (Munich, Germany)

Therapeutic range of NOAC – a new paradigm?
Sebastian Harder (Frankfurt, Germany)

18:30-19:00 **Panel discussion: NOAC antidotes**
Panel: ***Sebastian Harder*** (Frankfurt, Germany) - ***Basil Lewis*** (Tel Aviv, Israel) - ***Alexander Niessner*** (Vienna, Austria) - ***Giuseppe M.C. Rosano*** (London, UK) - ***Sven Wassmann*** (Munich, Germany)

Current status of antidotes and reversal agents for NOAC
Sven Wassmann (Munich, Germany)

Panel discussion

31 May 2015

9:00-10:00 **Drugs on the horizon for the treatment of cardiovascular disease**
Chairs: ***Vincenzo Mollace*** (Catanzaro, Italy) - ***Juan Tamargo*** (Madrid, Spain)

Lipid and glucose management
Heinz Drexel (Feldkirch, Austria)

Heart failure
Giuseppe M.C. Rosano (London, UK)

Treatment of hyperkalemia
Maurizio Volterrani (Rome, Italy)

10:00-10:30 **Coffee break and poster presentations**
Chair: ***Christian Torp-Pedersen*** (Aalborg, Denmark)

10:30-11:30 **How to manage chronic ischaemic heart disease**
Chairs: ***Claudio Ceconi*** (Ferrara, Italy)

Individualization of antiplatelet therapy: state-of-the-art
Nikita Lomakin (Moscow, Russia)

Disease modifiers and symptomatic therapy in patients with angina: the association for optimal medical therapy
Claudio Ceconi (Ferrara, Italy)

Symptoms vs. prognosis: is this the question?
Maurizio Volterrani (Rome, Italy)

11:30-12:30 **Debate session**
Chairs: ***Stefan Agewall*** (Oslo, Norway) - ***Claudio Ceconi*** (Ferrara, Italy)

Short versus long dual antiplatelet treatment after ACS/stenting?
Sven Wassmann (Munich, Germany) vs. ***Basil Lewis*** (Tel Aviv, Israel)

LDL cholesterol: the lower the better?
Heinz Drexel (Feldkirch, Austria)
vs. ***Christian Torp-Pedersen*** (Aalborg, Denmark)

12:30-12:45 **Closing remarks**
Stefan Agewall (Oslo, Norway) - ***Sven Wassmann*** (Munich, Germany)

12:45 **Lunch**

WORKING GROUP
SCIENTIFIC COMMITTEE

Chairperson:
Stefan Agewall (NORWAY)
Vice-Chairperson & Secretary:
Basil S. Lewis (ISRAEL)
Past-Chairperson:
Keld Per Kjeldsen (DENMARK)
Treasurer:
Christian Torp-Pedersen (DENMARK))

ORDINARY NUCLEUS MEMBERS

Claudio Ceconi (ITALY)
Heinz Drexel (AUSTRIA)
Christian Funck-Brentano (FRANCE)
Juan Carlos Kaski (UK)
Alexander Niessner (AUSTRIA)
Juan Tamargo (SPAIN)
Thomas Walther (IRELAND)

ASSOCIATE NUCLEUS MEMBERS

Dan Atar (NORWAY)
Maria Angeles Alonso Garcia (SPAIN)
Faiez Zannad (FRANCE)

EX-OFFICIO MEMBERS

Giuseppe Rosano (UK)
Harald Schmidt (THE NETHERLANDS)
Sven Wassmann (GERMANY)

FACULTY:

Agewall Stefan
Oslo, Norway
Andreotti Felicita
Rome, Italy
Anker stefan
Berlin, Germany
Biondi Zoccai Giuseppe
Latina, Italy
Bolognese Leonardo
Arezzo, Italy
Capodanno Davide
Catania, Italy
Ceconi Claudio
Ferrara, Italy
Danesi Alessandro
Rome, Italy
De Luca Giuseppe
Novara, Italy
De Luca Leonardo
Rome, Italy
Drexel Heinz
Feldkirch, Austria
Gaspardone Achille
Rome, Italy
Gioffre' Gaetano
Rome, Italy
Granatelli Antonino
Rome, Italy
Greco Cesare
Rome, Italy
Harder Sebastian
Frankfurt, Germany
Kaski Juan Carlos
London, UK
Lauro Davide
Rome, Italy
Lewis Basil
Tel Aviv, Israel
Lomakin Nikita
Moscow, Russia
Mac Lennar MaryCate
London, UK
Mancone Massimo
Rome, Italy
Metra Marco
Brescia, Italy
Miglionico Marco
Rome, Italy
Mollace Vincenzo
Catanzaro, Italy
Mugelli Alessandro
Florence, Italy
Niccoli Giampaolo
Rome, Italy
Niessner Alexander
Vienna, Austria
Parker Lucy
London, UK
Parodi Guido
Firenze, Italy
Pasceri Vincenzo
Rome, Italy
Pelliccia Francesco
Rome, Italy
Pristipino Christian
Rome, Italy
Rigattieri Stefano
Rome, Italy
Rolfe Debbie
London, UK
Rosano Giuseppe M.C.
London, UK
Sangiorgi Giuseppe Massimo
Rome, Italy
Sardella Gennaro
Rome, Italy
Savarese Gianluigi
Naples, Italy
Schiariti Michele
Rome, Italy
Scuteri Angelo
Rome, Italy
Speciale Giulio
Rome, Italy
Stefanini Giulio Giuseppe
Milan, Italy
Tamargo Juan
Madrid, Spain
Tomai Fabrizio
Rome, Italy
Torp-Pedersen Christian
Aalborg, Denmark
Trani Carlo
Rome, Italy
Viceconte Nicola
Rome, Italy
Volterrani Maurizio
Rome, Italy
Walther Thomas
Cork, Ireland
Wassmann Sven
Munich, Germany

We would like to thank the following sponsors for their support in organizing the third annual meeting

Boehringer Ingelheim
I.F.B. STRODER
NOVARTIS
SERVIER

eurocvp 2015 Congress

ROME 29-31 May 2015

CONGRESS VENUE

NH VITTORIO VENETO
Corso d'Italia, 1 - 00198 Rome (Italy)
Tel. +39 06 84951

REGISTRATION OPENING TIMES

Opening hours:

Friday, 29 May:	from 12:00 to 19:30
Saturday, 30 May:	from 08:30 to 19:00
Sunday, 31 May:	from 08:30 to 16:30

OFFICIAL LANGUAGE:

The official language of the Meeting will be English, with the exception the Italian of language Symposium.

OPENING TIME SLIDE CENTER

Opening hours:

Friday, 29 May:	from 12:00 to 19:30
Saturday, 30 May:	from 08:30 to 19:00
Sunday, 31 May:	from 08:30 to 16:30

LUNCHES AND COFFEE BREAKS

Coffee breaks will be served in the Ground Floor Bar Area.
Access to the Restaurant is reserved for delegates in possession of lunch coupons.

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be provided to all registered attendants at the registration desk.

BADGES

Badges will be distributed at the registration desk.
Participants without badges will not be admitted to any congress related activities.

SOCIAL DINNER

Please enquire at the registration desk for details and tickets to the dinners on 29th and 30th May.

ORGANIZING SECRETARIAT

MICOM COMUNICAZIONE INTEGRATA

Via Bernardino Verro 12
20141 Milan - Italy
Tel. +39 0289518895
Email: eurocvp@micom.it
Web: www.eurocvp.com

SCIENTIFIC SECRETARIAT

Cardiovascular Pharmacotherapy ESC Working Group

EUROPEAN SOCIETY OF CARDIOLOGY®

all about clinical trials

ROME 29-30 May 2015

29 May

09:00 - 10:15 REGISTRATION

10:15 - 10:30 Welcome, introduction and course objectives
Juan Carlos Kaski (London, UK)
Giuseppe M.C. Rosano (London, UK)
Sven Wassmann (Munich, Germany)

SESSION 1. HOW TO DESIGN A CLINICAL TRIAL

10:30 - 11:00 An overview of the different aspects of clinical trials
Claudio Ceconi (Ferrara, Italy)

11:00 - 11:30 Traditional versus novel trial designing
Giuseppe M.C. Rosano (London, UK)

11:30 - 12:00 Refreshments and networking

12:00 - 12:30 The objectives, the site, the finance and the role of the ethics committee and research organization
Basil Lewis (Tel Aviv, Israel)

SESSION 2. REGULATORY ASPECTS

12:30 - 13:00 Requirements from regulatory agencies: endpoints, comparators, type of studies
Giuseppe M.C. Rosano (London, UK)

13:00 - 13:30 Post marketing surveillance
Claudio Ceconi (Ferrara, Italy)

13:30 - 14:30 Lunch and networking

SESSION 3. HOW TO RUN A TRIAL EFFICIENTLY

14:30 - 15:00 The role of the principal investigator: keys to success, perils and tribulations
Heinz Drexel (Feldkirk, Austria)

15:00 - 15:30 The team, the procedures, the monitor and the sponsor
MaryCate MacLennan (London, UK)

15:30 - 16:00 The role of the research office
Lucy Parker (London, UK)

16:00 - 16:30 Refreshments and networking

SESSION 4. TRIAL CATEGORIES

16:30 - 17:15 Randomised controlled trials and registries
Christian Torp-Pedersen (Aalborg, Denmark)

17:15 - 18:00 Meta-analyses and systematic reviews
Gianluigi Savarese (Naples, Italy)

18:00 Close of day 1
Refreshments and networking

30 May

8:15 - 8:30 Welcome and objectives
Francesco Pelliccia (Rome, Italy)
Giuseppe M.C. Rosano (London, UK)
Sven Wassmann (Munich, Germany)

8:30 - 10:30 GOOD CLINICAL PRACTICE
Debbie Rolfe (London, UK)

10:30 - 11:00 Refreshments and networking

11:00 - 12:30 HOW TO INTERPRET CLINICAL TRIAL DATA
Examples from recent trials
Sven Wassmann (Munich, Germany)
Claudio Ceconi (Ferrara, Italy)

12:30 - 13:30 HOW TO WRITE A MANUSCRIPT:
HOW TO MAKE THE MOST OF YOUR DATA
Basil Lewis (Tel Aviv, Israel)
Giuseppe M.C. Rosano (London, UK)

- Selecting the appropriate journal
- How to structure and format the manuscript, organise the data, prepare figures and tables, discuss the findings, write the conclusions and abstract
- Characteristics of a good manuscript
- How to increase the chance of getting it accepted
- Perspectives of an Editor-in-Chief

13:30 - 13:45 Certificates and closing remarks
Francesco Pelliccia (Rome, Italy)
Giuseppe M.C. Rosano (London, UK)
Sven Wassmann (Munich, Germany)

13.45 Closing remarks

Cardiovascular Pharmacotherapy ESC Working Group

EUROPEAN SOCIETY OF CARDIOLOGY®

all about clinical trials

ROME 29-30 May 2015

The European Society of Cardiology is proud to be delivering an engaging and interactive 2-day course to improve the professional knowledge and skills required to plan and deliver successful cardiovascular pharmacotherapy clinical trials.

Our goal is for all participants to leave the meeting with the improved competence and confidence to deliver better clinical trials which in turn will have a positive impact on services and patient outcomes.

This course is aimed at improving knowledge and skills related to clinical trial planning and design as well as the successful running of different types of clinical trials. We will offer highly interactive sessions coordinated by top experts in their fields. In addition, the course will offer interactive workshops on Good Clinical Practice (GCP), regulatory issues, statistics, trial data interpretation and manuscript writing.

At the end of the course delegates will be able to:

- design and plan successful clinical trials,
- evaluate and follow the correct processes and regulatory procedures,
- effectively analyse and interpret data.

This course will be an excellent opportunity for education, networking and creating opportunities.

Course directors

Giuseppe MC Rosano, MD, PhD, FESC
Sven Wassmann, MD, PhD, FESC
Juan Carlos Kaski, DSc, DM (Hons), MD, FRCP, FESC

ORGANISED BY THE WORKING GROUP ON CARDIOVASCULAR PHARMACOTHERAPY OF THE EUROPEAN SOCIETY OF CARDIOLOGY

Cardiovascular Pharmacotherapy
ESC Working Group

EUROPEAN SOCIETY OF CARDIOLOGY®